

# Alexander G. Lucaci

---

email: alexander.lucaci@temple.edu

website: aglucaci.github.io

ORCID: 0000-0002-4896-6088

## EDUCATION

*Ph.D. Candidate in Bioinformatics*

2018 - Present

Temple University

Institute for Genomics Evolutionary Medicine (iGEM)

Dissertation mentored by Dr. Sergei Pond

*M.S. in Biology*

2016-2018

New York University

*B.S. in Biochemistry*

2011

Stony Brook University

## EXPERIENCE

*Temple University*

Spring 2022-Present

Graduate Research Assistant

- Development, validation, and application of statistical methods which evaluate the effects of mutational events on the inference of evolutionary rates.

*Maxim Group*

Fall 2021 - Present

Intern - Biotechnology Equity Research

- Initiate coverage on companies with investment recommendations based on fundamental analysis. Modeling companies under coverage using financial valuation methods and report on company earnings.

*Temple University*

Fall 2021

Graduate Teaching Assistant - Genomics in Medicine

- Directed over one hundred and fifty students in a cross-listed (Graduate and Undergraduate) course in a virtual format. Responsible for teaching material, grading, quizzes and exams, holding office hours and guidance on assignments

*ROTH Capital Partners*

Spring 2018

Intern - Healthcare Investment Banking

- Participated in the process IPO process for a NASDAQ listed company. Responsible for current healthcare IPO market data, curating pitch decks for senior managers and research for (M&A) deals.

## SELECTED

## PUBLICATIONS

1. *Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa* (Accepted at Nature)

2. *The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape* (Accepted at Cell)

3. *Extra base hits: widespread empirical support for instantaneous multiple-nucleotide changes* (Accepted at PLOS One)

4. *Human HspB1, HspB3, HspB5 and HspB8: Shaping these Disease Factors during Vertebrate Evolution* (submitted)

5. *RASCL: Rapid assessment of SARS-COV-2 clades enabled through molecular sequence analysis* (manuscript in preparation)